ReSynapse is developing precision multi-target serotonin modulators that represent a new therapeutic category for depression and treatment-resistant cases. ReSynapse's unique receptor combination and precise modulation modes target validated pathways for rapid neuroplasticity while avoiding side-effect receptors. Our big-data SerotoninDB platform features rational multi-target drug design through advanced computational chemistry, and 60 billion compound screening with unprecedented accuracy. Our mission is fast-acting, long-lasting therapeutics that address critical unmet medical needs.